DS-01® comprises 24 scientifically studied probiotic strains with a patented, non-fiber prebiotic. This breakthrough formulation is paired with innovations in probiotic stabilization and a precision-release system to deliver strains to the lower small intestine and colon, which support systemic benefits and whole body health.*

Formulation

Bifidobacterium breve SD-BR3-IT

Bifidobacterium longum SD-BB536-JP

Lacticaseibacillus rhamnosus HRVD113-US

Lactiplantibacillus plantarum SD-LP1-IT


Lacticaseibacillus rhamnosus SD-LR6-IT

Bifidobacterium lactis HRVD524-US

Bifidobacterium infantis SD-M63-JP

Bifidobacterium lactis SD-BS5-IT

Lacticaseibacillus casei HRVD300-US

Bifidobacterium breve HRVD521-US

Bifidobacterium lactis SD-150-BE

Bifidobacterium longum HRVD90b-US

Lacticaseibacillus rhamnosus SD-GG-BE

Limosilactobacillus reuteri RD830-FR

Lactobacillus crispatus SD-LCR01-IT

Limosilactobacillus fermentum SD-LF8-IT

Bifidobacterium adolescentis SD-BA5-IT

Limosilactobacillus reuteri SD-LRE2-IT 

Ligilactobacillus salivarius SD-LS1-IT

Bifidobacterium longum SD-CECT7347-SP

Lacticaseibacillus casei SD-CECT9104-SP

Bifidobacterium lactis SD-CECT8145-SP

Lactiplantibacillus plantarum SD-LPLDL-UK

Bifidobacterium lactis SD-MB2409-IT

Indian Pomegranate [whole fruit] (Punica granatum) (>40% Polyphenolic + Phenolic Bioactives)

*Identical strain, formerly known as Bifidobacterium adolescentis SD-BA5-IT

Directions for Use

Take 1 capsule daily for the first three days.

On day four (or when you’re ready), increase to the full dose of 2 capsules at once, daily. Ideally, take both capsules on an empty stomach or at least 10 minutes prior to a meal.

seed image-acclimation-protocol-large
Fig. 1 — Acclimation protocol
seed image-acclimation-protocol-small
Fig. 1 — Acclimation protocol

Just as with any new diet, product, or change, you may experience a temporary acclimation period—some gastrointestinal discomfort, abdominal tightness, mild nausea, or changes in your stool. This can be very normal. In fact, an immediate physiological reaction is a sign that our probiotics are viable and attuning to your system. Any discomfort should subside within the first few weeks of consistent use.

If the discomfort does not subside, you may try experimenting with your DS-01® use. Try taking the capsules with food or one capsule in the morning and one in the evening.

Clinical Trials

DS-01® on Bloating and Irregularity

Bloating, gas, and irregular bowel habits are among the most common gastrointestinal complaints in the general population — yet most probiotic clinical research focuses on individuals with diagnosed GI conditions. Generally healthy adults experiencing these symptoms represent a significant, underserved population in the clinical literature. To address this gap, we conducted a randomized, double-blind, placebo-controlled trial in 350 generally healthy adults experiencing bloating/indigestion. Over 6 weeks, participants were evaluated for GI complaints and burden, including using validated clinical endpoints.

Participants taking DS-01 demonstrated a statistically significant reduction in bloating and gas compared to placebo, as measured by the NIH-GI PROMIS 13a. DS-01 also led to meaningful reductions in abdominal discomfort relative to placebo, assessed via the NIH-GI PROMIS 5a. In terms of bowel habits, DS-01 supported improved regularity compared to placebo, with observed improvements in occasional constipation-related discomfort. Beyond symptom-level metrics, DS-01 improved GI-related quality of life compared to placebo as measured by the DQLQ — including greater food enjoyment, reduced food avoidance, and less disruption to physical activity due to digestive events, outcomes that reflect how digestive health is actually experienced in daily life.

By applying the same clinically rigorous tools used in GI condition research to a generally healthy population, at a scale not previously achieved in this category, this study established a higher evidentiary standard for what probiotic science can demonstrate. The findings show that the known mechanistic activity of DS-01 translates to real, measurable improvements in how people feel — across a population that has historically been excluded from this research.

Allegretty JR, et al. Nutrients. 2026 Jan 14;18(2):255 

Learn about additional clinical trials supporting DS-01 here 


Napier et al., Digestive Disease Week 2024

Other Full-formulation Clinical Trials

Napier BA, Allegretti JR, Feuerstadt P, Kelly CR, Van Hise NW, Jäger R, Kassam Z, Reid G. Multi-Species Synbiotic Supplementation Enhances Gut Microbial Diversity, Increases Urolithin A and Butyrate Production, and Reduces Inflammation in Healthy Adults: A Randomized, Placebo-Controlled Trial. Nutrients. 2025 Aug 23;17(17):2734

Napier BA, Allegretti JR, Feuerstadt P, Kelly CR, Van Hise NW, Jäger R, Stuivenberg GA, Kassam Z, Reid G. Multi-Species Synbiotic Supplementation After Antibiotics Promotes Recovery of Microbial Diversity and Function, and Increases Gut Barrier Integrity: A Randomized, Placebo-Controlled Trial. Antibiotics. 2026; 15(2):138

Napier BA, Van Den Elzen C, Al-Ghalith GA, Avena CV, Gevers D, Dhir R, Nee J, Lembo A, Simmons S. A Multi-Species Synbiotic (DS-01) Alleviates Irritable Bowel Syndrome Symptoms While Boosting Synbiotic Consortium: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Digestive Disease Week. 2024 

Strain-Specific Benefit Studies

BenefitStudies
Digestive HealthDel Piano et al. J Clin Gastroenterol. 2010
Ogata et al. Biosci Microflora. 1997
Gut Barrier IntegrityIemoli et al. J Clin Gastroenterol. 2012 ‡
Magistrelli et al. Front Immunol.2019††
Gut Immune AxisOlivares et al. J Agric Food Chem. 2011
Iemoli et al. J Clin Gastroenterol. 2012‡
Drago et al. Allergy Asthma Immunol Res. 2015
Magistrelli et al. Front Immunol.
Cardiovascular HealthCostabile et al. PLoS One. 2017
Bordoni et al. Appl Microbiol Biotechnol. 2013
Keleszade et al. J Func Foods. 2022
Dermatological HealthIemoli et al. J Clin Gastroenterol. 2012‡
Climent et al. Microorganisms. 2021†††
Navarro-López et al. JAMA Dermatol. 2018†††
Micronutrient SynthesisBron et al. I J Mol Sciences. 2021
Strozzi & Mogna. J Clin Gastroenterol. 2008
Pompei et al. Appl Environ Microbiol. 2007
Gut Microbial BalanceDrago et al. Allergy Asthma Immunol Res. 2015
Magistrelli et al. Front Immunol. 2019††
BenefitStudies
Digestive HealthDel Piano et al. J Clin Gastroenterol. 2010
Ogata et al. Biosci Microflora. 1997
Gut Barrier IntegrityIemoli et al. J Clin Gastroenterol. 2012 ‡
Magistrelli et al. Front Immunol.2019††
Gut Immune AxisOlivares et al. J Agric Food Chem. 2011
Iemoli et al. J Clin Gastroenterol. 2012‡
Drago et al. Allergy Asthma Immunol Res. 2015
Magistrelli et al. Front Immunol.
Cardiovascular HealthCostabile et al. PLoS One. 2017
Bordoni et al. Appl Microbiol Biotechnol. 2013
Keleszade et al. J Func Foods. 2022
Dermatological HealthIemoli et al. J Clin Gastroenterol. 2012‡
Climent et al. Microorganisms. 2021†††
Navarro-López et al. JAMA Dermatol. 2018†††
Micronutrient SynthesisPompei et al. Appl Environ Microbiol. 2008
Pompei et al. Appl Environ Microbiol. 2007
Gut Microbial BalanceDrago et al. Allergy Asthma Immunol Res. 2015
Magistrelli et al. Front Immunol. 2019††
seed Fig. 4 — Strain microscopy: 1 <i>Lactobacillus rhamnosus</i> SD-LR6-IT, 2 <i>Lactobacillus plantarum</i> SD-LPLDL-UK, 3 <i>Bifidobacterium longum</i> SD-CECT7347-SP1
seed Fig. 4 — Strain microscopy: 1 <i>Lactobacillus rhamnosus</i> SD-LR6-IT, 2 <i>Lactobacillus plantarum</i> SD-LPLDL-UK, 3 <i>Bifidobacterium longum</i> SD-CECT7347-SP2
seed Fig. 4 — Strain microscopy: 1 <i>Lactobacillus rhamnosus</i> SD-LR6-IT, 2 <i>Lactobacillus plantarum</i> SD-LPLDL-UK, 3 <i>Bifidobacterium longum</i> SD-CECT7347-SP3
Fig. 4 — Strain microscopy: 1 Lactobacillus rhamnosus SD-LR6-IT, 2 Lactobacillus plantarum SD-LPLDL-UK, 3 Bifidobacterium longum SD-CECT7347-SP

Testing

Quality Control Testing Battery

Microbiological DataDescriptionUnit of Measure (LOQ)Testing Frequency
Yeasts and molds<100 CFU/gEach batch
Enterobacteria<10 MPN/gEach batch
Total coliforms<3 MPN/gEach batch
E. coliAbsent/ 10 gEach batch
SalmonellaAbsent/ 25 gEach batch
Staphylococcus coagulase positive<10 CFU/gEach batch
Listeria monocytogenesNegative/ 25 gEach batch
DescriptionUnit of Measure (LOQ)Testing Frequency
Yeasts and molds<100 CFU/gEach batch
Enterobacteria<10 MPN/gEach batch
Total coliforms<3 MPN/gEach batch
E. coliAbsent/ 10 gEach batch
SalmonellaAbsent/ 25 gEach batch
Staphylococcus coagulase positive<10 CFU/gEach batch
Listeria monocytogenesNegative/ 25 gEach batch
Chemical Contaminants
[Organic]
DescriptionTesting Frequency
AMPA (breakdown product of glyphosate)Quarterly
GlyphosateQuarterly
Pesticides/Biocides [427 different chemicals]Quarterly
DescriptionUnit of Measure (LOQ)Testing Frequency
AMPA (breakdown product of glyphosate)<10.0 ng/gQuarterly
Glyphosate<10.0 ng/gQuarterly
Pesticides/Biocides [427 different chemicals]Varies; see Pesticides List in Appendix Section IIIQuarterly
AllergenDS-01™
Daily Dose
Testing Frequency
Almond<0.1mgQuarterly
Brazil Nut<0.1mgQuarterly
Cashew<0.05mgQuarterly
Celery<0.07mgQuarterly
CornNot established*Quarterly
Gluten [across barley, rye, oats + wheat] (wheat protein)<20 ppmQuarterly
Crustacean (shrimp protein)<26.2mgQuarterly
Egg<0.2mgQuarterly
Fish<2.6mgQuarterly
Hazelnut<0.1mgQuarterly
Lupin<2.9mgQuarterly
Macadamia Nut<0.1mgQuarterly
Milk<0.2mgQuarterly
MolluscsNot established*Quarterly
Mustard<0.07mgQuarterly
Peanut<0.2mgQuarterly
Pecan<0.03mgQuarterly
Pine Nut<0.1mgQuarterly
Pistachio<0.05mgQuarterly
Sesame<0.1mgQuarterly
Soy<0.5mgQuarterly
Sulfiting Agents<10 ppmQuarterly
Walnut<0.03mgQuarterly
AllergenDS-01™
Daily Dose
Testing Frequency
Almond<0.1mgQuarterly
Brazil Nut<0.1mgQuarterly
Cashew<0.05mgQuarterly
Celery<0.07mgQuarterly
CornNot established*Quarterly
Gluten [across barley, rye, oats + wheat] (wheat protein)<20 ppmQuarterly
Crustacean (shrimp protein)<26.2mgQuarterly
Egg<0.2mgQuarterly
Fish<2.6mgQuarterly
Hazelnut<0.1mgQuarterly
Lupin<2.9mgQuarterly
Macadamia Nut<0.1mgQuarterly
Milk<0.2mgQuarterly
MolluscsNot established*Quarterly
Mustard<0.07mgQuarterly
Peanut<0.2mgQuarterly
Pecan<0.03mgQuarterly
Pine Nut<0.1mgQuarterly
Pistachio<0.05mgQuarterly
Sesame<0.1mgQuarterly
Soy<0.5mgQuarterly
Sulfiting Agents<10 ppmQuarterly
Walnut<0.03mgQuarterly

‡Maximum daily doses are clinically-derived from oral food challenge studies and reflect the most recent advancements in food allergy research.  The reference dose, also termed ED01, is the dose at which 1% of the allergic population would be predicted to experience any objective allergic reaction (i.e., 99% of the population does not experience any objectively measurable reaction).

*Inadequate number of clinical studies using low dose oral challenges with this allergen.


Whole Genome SequencingDescriptionUnit of Measure (LOQ)Testing Frequency
A series of involved genetic tests down to the strain level≥ Label claim for AFU (strain specific)Under development
DescriptionUnit of Measure (LOQ)Testing Frequency
A series of involved genetic tests down to the strain level≥ Label claim for AFU (strain specific)Under development
Water ActivityDescriptionUnit of Measure (LOQ)Testing Frequency
(aW) - Dew Point Method< 0.20 aW (inner and outer cap)Each batch
DescriptionUnit of Measure (LOQ)Testing Frequency
(aW) - Dew Point Method< 0.20 aW (inner and outer cap)Each batch

DS-01® is tested for all 14 classes of allergens according to EFSA and verified to be below the ED01.

At the three hour mark of incubation, the ViaCap® delivered a maximal release of probiotics maintaining the full value of the starting dose (10.57 log vs 10.60 log, or about 100%), indicating viability through the end of the small intestine for delivery into the colon. The ViaCap® was engineered for a precision release of the contents of the inner, probiotic capsule, through the small intestine, resulting in full delivery of label potency prior to entering the colon chamber.

seed
seed
seed
seed
seed
seed

Interactions

DS-01® has no known contraindications with medications or supplements. However, if you are currently taking prescription medication, have an underlying medical condition, are pregnant or nursing, or if you have questions regarding your specific health needs, you should consult with your personal physician prior to use so that they may advise with the complete knowledge of your health history.

Can I take too many probiotics?

Unlike with some vitamins and minerals, probiotics do not have established recommended upper limits, and clinical literature has not generally shown them to reach levels of toxicity. In fact, probiotics have been clinically studied for certain indications in CFU dosages that reach the trillions. It is important to note, more is not necessarily better—the best dose per strain is the one shown in human clinical trials to have the intended health benefit. 

Can I take DS-01® with other probiotics?

Many DS-01® users take other supplements, including additional probiotics. While there are no known adverse effects from combining these formulations, there may be some functional redundancy when combining microbial strains in the Lactobacillus and Bifidobacteria genera. To ensure a streamlined and effective protocol, we suggest reviewing your full supplement regimen with your physician or a healthcare professional.